invest summari qualiti beat rais quarter reiter
ow rate price target share given compani
durabl busi model posit outlook macro factor think
multipl hold upward earn revis drive share higher
think multipl support durabl busi model posit
outlook macro factor solid execut manag upward earn
revis could come higher-than-anticip peak sale new launch
better-than-expect oper margin
posit quarter support thesi deliv
oper growth exclud impact fx revenu
oper growth adjust net incom strong perform
driven new parasiticid vaccin dermatolog
increas guidanc reflect addit abaxi chang
fx intern speci contribut growth cattl swine
product perform particularli well growth cattl product driven
favor market condit canada uk sever smaller emerg
market also contribut growth sale increas yoy sale
companion anim product grew driven dermatolog portfolio
simparica complet acquisit abaxi deal enhanc
presenc veterinari diagnost categori anim health industri
compound-annual-growth-rate sale abaxi total repres
yoy growth see big opportun livestock diagnost
announc five-year agreement cover develop
mab expand leadership
report ep factset consensu
higher estim increas ep guidanc rang
factset consensu updat
financi model increas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price target
restrict ban use antibacteri food-produc anim may
becom preval zoeti current sell antibacteri product govern
consum begun shift away consum prefer and/or govern
regul grow may affect zoetiss abil meet forecast
advers weather condit avail natur resourc could drive
price feed expens compon produc feed price rise
profit fall zoetiss custom may spend less anim health drug
lack new product launch and/or exist product fail gain market share
street good expect zoetiss new launch compani perform
line better expect could downsid risk number
macro factor weather feed price currenc could advers impact sale
earn zoeti off-set sinc global busi said macro factor
global could pressur earn
oper margin expans lower expect zoeti still gross margin
expans expect compani meet target and/or
margin improv seen to-dat sustain could downsid number
brand and/or gener competit key drug zoeti face competit could
headwind sale given larg number product portfolio compani
strong relationship custom see smaller type risk
bull bear base case analysi
use dcf multipl price-to-earnings analysi arriv bull bear case scenario
base analysi estim likelihood stock worth next
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casenew launch better expectedmargin improv better expectedmacro factor improvestrateg busi scenario casenew launch in-lin expectationsmargin improv in-lin expectationsmacro factor remain stableno busi scenario casenew launch expectationsmargin improv expectationsheadwind macro factor busi scenario exhibit varianc analysi
amount chang yoyamount chang growth driven dermatolog portfolio simparica livestock product growth poultri increas sale across multipl market companion anim livestock product total gross oper oper non oper pre-tax tax net averag cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom patent start expir sarolan label expans includ deer investor dayportfolio strategi trioapprov launch european collabor licens agreement expir year ipo antiparasit process patent expir increas manufactur strategycomplet step two focus excel patent set patent set strategycomplet step three invest growthsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
outlook us oper cost sale percentag sg interest expens tax rate adjust dilut net signific item acquisition-rel cantor fitzgerald research compani expect improv gross margin come expect swine fish livestock market growth expect reach peak sale year dermatolog apoquel cytopoint expect cytopoint sale reach blockbust guidanc reflect foreign exchang rate mid-juli includ partial year impact abaxi lastfiv month year month organ growth exclud impact foreign expect profit growth livestock april june abaxi compani report sale repres yoy unfavor foreign exchang rate impact sale exclud abaxi expect oper growth abaxi expect oper growth expect headwind growth due strong base four fewer sell day vs abaxi deal close per share cash aggreg exhibit incom statement analysi
million except per share amount compound-annual-growth-rate year end decemb oper incom incom non-control incom attribut non-controlling net dilut changetot dilut cantor fitzgerald research compani report
exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb new cantor fitzgerald research compani report exhibit annual sale analysi
new cantor fitzgerald research compani reportsyear end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci includ cash separ intern cost net chang work net cash provid oper flow invest activitiespurchas net proce sale acquisit net cash other- net cash use invest flow financ activ repay issuanc long term dividend net cash use provid financ effect exchange-r cash net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt current defer tax assets- current total current plant properti identifi total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling total liabil stockhold sourc cantor fitzgerald research compani report august
zoeti anim health compani focus discoveri develop manufactur commerci anim health medicin
vaccin across livestock companion anim zoeti directli market product countri product sold
countri world-wide zoeti focuss eight core speci cattl swine poultri sheep fish form part compani
livestock segment dog cat hors manag compani companion anim segment zoetiss five major product
categori within segment anti-infect vaccin parasiticid medic feed addit pharmaceut
